1,312 results on '"Hillmen P."'
Search Results
102. A single-centre experience of treating adult patients with Langerhans’ cell histiocytosis and Erdheim Chester disease: sustained response to oral methotrexate in frontline and relapsed disease: 15
103. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry
104. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
105. UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY
106. FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
107. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2
108. Forty-eight week efficacy and safety of pegcetacoplan in adult patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to prior eculizumab treatment
109. Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion.
110. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
111. Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
112. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
113. Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab
114. Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?
115. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted): 37
116. Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses: 34
117. Insights into the natural history of paroxysmal nocturnal hemoglobinuria (PNH): analysis of the presenting clinical, haematological and flow cytometric features of 705 patients leads to improved classification and prediction of clinical course: 24
118. Coversin, a small protein complement inhibitor, is a potential novel anti-thrombotic agent: 5
119. A phase 3, randomized, double-blind, placebocontrolled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375): 4
120. Immunophenotypic assessment of PNHclones in major and minor cell lineages in the peripheral blood of patients with paroxysmal nocturnal hemoglobinuria
121. Assessing minimal residual disease in chronic lymphocytic leukemia
122. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
123. Prognostic or predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
124. Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab
125. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial
126. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: Results complement1 from the pivotal phase III study
127. Results of the PEGASUS phase 3 randomized trial demonstrating superiority of the C3 inhibitor, pegcetacoplan, compared to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH)
128. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens
129. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
130. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
131. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
132. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
133. Experiences in the design and implementation of phase II trials in CLL
134. The evolving role of Alemtuzumab in management of patients with CLL
135. Antibody Responses After First and Second COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukaemia
136. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
137. RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
138. Eculizumab in paroxysmal nocturnal haemoglobinuria (PNH): a report of all 153 patients treated in the UK: 8
139. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria
140. Immunological effects and safe administration of alemtuzumab (MabCampath™) in advanced B-CLL
141. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
142. Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria
143. The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the randomised UK National Cancer Research Institute (NCRI) trial: 26
144. Final response assessment of the CLL208 trial: an open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL).: 43
145. NCRN CLL207 study of alemtuzumab consolidation in chronic lymphocytic leukaemia: final response assessment and early follow-up (on behalf of the NCRI CLL Trials Sub-Group): 16
146. Paroxysmal nocturnal haemoglobinuria reveals a role for glycosylphosphatidylinositol-linked molecules in the function and peripheral homeostasis of human NK cell subsets: 55
147. Long term treatment with eculizumab in paroxysmal nocturnal haemoglobinuria (PNH): sustained efficacy and improved survival: 54
148. Kinobead Profiling Reveals Reprogramming of B-cell Receptor Signaling in Response to Therapy Within Primary Chronic Lymphocytic Leukemia Cells
149. Achieving minimal residual disease (MRD) negativity in CLL is independently associated with improved progression-free and overall survival and is an appropriate end-point of therapy: 41
150. A spontaneous reduction of clone size in paroxysmal nocturnal haemoglobinuria patients treated with eculizumab for greater than 12 months: 24
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.